The transport characteristics of the placenta, which favour higher phenylalanine concentrations in the fetus than in the mother, and regression data of head circumference at birth against phenylalanine concentration at conception in maternal phenylketonuria (PKU), suggest that treatment of maternal PKU should ideally aim to maintain plasma phenylalanine concentration within the normal range throughout pregnancy. A patient with classical PKU was treated from before conception by aiming to maintain plasma phenylalanine concentration within the range 50-150 tmol/I and tyrosine within the range 60-90 itmol/l.
developing fetal brain is likely to be at least as sensitive, if not more so, to damage by increased phenylalanine concentrations as that of the infant. These considerations would favour maintenance of maternal phenylalanine concentration at or below 50% of the recommended treatment range for infancy. This concept is taken further by regression data of phenylalanine concentration at conception in women with PKU against head circumference of offspring.' These data have recently been extended to show that head circumference at birth falls by 0-46 cm for every 200 iimol/l rise in phenylalanine concentration above normal. 7 It has therefore been suggested that plasma phenylalanine concentration should be maintained in the normal range throughout pregnancy in a woman with PKU. 7 We now report management and outcome of pregnancy in a woman with PKU using these principles. The limited sensitivity of the filter paper blood spot assay method8 led us to use the more precise method of automated amino acid analysis to monitor plasma amino acid concentrations, aiming for a therapeutic control range for phenylalanine of between 50-150 ,imol/l and for tyrosine of between 60-90 ,umol/l (that is, within the upper normal range). The rationale for control of tyrosine concentration was based on the remarkable inhibition of tyrosine transport into placental brush border membrane vesicles with increasing concentrations of phenylalanine.9
The dietary management of phenylketonuria (PKU) both in infancy and in pregnancy has generally been monitored by measurement of phenylalanine concentrations using filter paper blood spot specimens. The While mounting circumstantial evidence suggests that plasma phenylalanine concentrations should be better controlled during pregnancy than is necessary for treatment of childhood PKU,7 the exact optimal range is yet to be determined. We have demonstrated that the accuracy of amino acid analyser determinations of plasma phenylalanine and tyrosine concentration can result in very precise control of blood phenylalanine and tyrosine in PKU. The therapeutic range aimed for in this patient (phenylalanine 50-150 ,umol/l, tyrosine [tmol/l) overlaps with that for normal pregnancy (phenylalanine 66-107 ,umol/l, tyrosine 40-76 ,umol/l, n=7, second trimester, personal communication, Dr E F Robertson).
No abnormality has been detected in the baby born to our patient. Head circumference measurements appear to be a sensitive indicator of outcome in maternal PKU6 ' and on this measure the baby is normal. This conclusion is supported by a normal developmental assessment at 1 year of age. Nevertheless, complete evaluation of the strategy of maintaining normal phenylalanine concentration in maternal PKU will not be possible until a much larger number of cases similar to ours have been described and followed up long term.
At several points during the current pregnancy, compliance and communication difficulties resulted in phenylalanine concentrations falling outside the intended therapeutic range. Early in the pregnancy concentrations rose to 271 and 266 [tmol/l at 9 and 10 weeks' gestation respectively. In a second pregnant PKU patient currently under treatment by the authors the phenylalanine concentration was well controlled before conception with a dietary phenylalanine intake of about 4 mg/kg/day, but the concentration rose to about 200 [tmol/l in the middle of the first trimester. In both patients the first trimester increases most likely reflected difficulty in maintaining energy intake because of morning sickness of pregnancy. Our experience in conventional management of PKU pregnancy indicates that phenylalanine concentrations can be difficult to control in the first trimester. In the patient currently under treatment, control of the phenylalanine concentration within the desired range was obtained when an energy supplement in the form of glucose polymer (Polyjoule, Sharpe Laboratories, 100 g/day) was added to the regimen.
Very low phenylalanine concentrations were also documented on several occasions, despite which no symptoms of phenylalanine deficiency were noted in the mother and the baby continued to grow satisfactorily. The ability to concentrate phenylalanine across the placenta in favour of the fetus' may protect the fetus from the effects of borderline maternal phenylalanine deficiency. Nevertheless, the potential risks of low phenylalanine concentration indicate the need for careful attention to increasing phenylalanine requirements, particularly during the second trimester. The narrow therapeutic range also requires accurate calculation of all dietary sources of phenylalanine including low phenylalanine bread, pasta, and biscuits and fruits and vegetables. Some of these foods are permitted without measurement in the diet of children with PKU on the basis that an average consumption provides a relatively constant intake of phenylalanine.
Tyrosine is a neurotransmitter precursor and low neurotransmitter concentrations have been suggested as one of the mechanisms by which damage may occur in PKU. 16 An optimal range for plasma tyrosine concentration in pregnancy of a woman with PKU has not been established. The potential for even small rises in plasma phenylalanine concentration to inhibit placental tyrosine transport8 suggests that maintenance of tyrosine concentrations in the upper normal range may be ideal. Treatment with a tyrosine fortified formula such as Maxamum XP with additional tyrosine supplements as required seems a satisfactory approach. The tyrosine concentration bore no consistent relationship to that of phenylalanine, presumably because the intake of each respective amino acid was adjusted independently in response to changes in blood concentrations. An unusually high tyrosine concentration (162 ,umol/l) was recorded at 23 weeks. There was no clear explanation for this increase. However, it is likely that the concentration was even higher one to two hours postprandially on this occasion and the possibility that raised tyrosine concentrations may in themselves cause fetal damage should not be ignored. 17 Excessive tyrosine supplementation should be avoided. In summary, we have now documented for the first time implementation of a frequently discussed strategy of maintaining normal phenylalanine concentrations in maternal PKU. Early indications suggest a normal outcome, although long term follow up of this and subsequent cases will be needed to determine the advantages of this strategy as compared with those of more conventional treatment methods. Our experience coupled with solid theoretical background suggests that these further studies should be undertaken.
